NCT00274508已完成3 期
Effect of Tiotropium on Exercise Tolerance and Static and Dynamic Lung Volumes in COPD Patients (A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study)
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 261
- 试验地点
- 28
- 主要终点
- Endurance time during a constant work rate exercise test to symptom limitation
研究概览
简要总结
To investigate whether tiotropium (Spiriva) improves exercise endurance in patients with COPD
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 40 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female patients with a clinical diagnosis of Chronic Obstructive Pulmonary Disease (COPD) based on American Thoracic Society (ATS) guidelines with:
- •Relatively stable, moderate to severe airway obstruction with an Forced Expiratory Volume in One Second (FEV1) less than or equal to 65% of predicted normal (determined at Visit 1).
- •Presence of lung hyperinflation as demonstrated by Functional Residual Capacity determined by body plethysmography (TGV(FRC)) greater than or equal to 120% of predicted normal (determined at Visit 1).
- •Age greater or equal to 40 years and less than or equal to 75 years.
- •A cigarette smoking history of more than ten pack-years. A pack-year was defined as the equivalent of smoking one pack of cigarettes per day for a year.
- •Able to perform all specified procedures and able to maintain all necessary records during the study period as required in the protocol.
- •Able to inhale the trial medication from the HandiHaler device.
排除标准
- •Patients with a significant disease other than COPD. A significant disease was defined as a disease which, in the opinion of the investigator, may have put the patient at risk because of participation in the trial or may have influenced the results of the trial or the patient's ability to participate in the trial.
- •Patients with clinically significant abnormal baseline hematology, blood chemistry or urinalysis. If the abnormality defined a disease listed as an exclusion criterion, the patient was excluded.
- •Patients with Serum Glutamic Oxaloacetic Transaminase (SGOT) ≥1.5 x ULN (upper limit of normal range), Serum Glutamic Pyruvic Transaminase (SGPT) ≥1.5 x ULN bilirubin ≥1.5 x ULN or creatinine ≥1.5 x ULN were excluded regardless of the clinical condition.
- •Patients with a recent history (i.e., 1 year or less) of myocardial infarction.
- •Patients with a recent history (i.e., 3 years or less) of heart failure, pulmonary edema, or patients with cardiac arrhythmia (with or without symptoms) or any contraindication to exercise.
- •Patients requiring the regular use of daytime oxygen therapy.
- •Patients with known active tuberculosis.
- •Patients with a history of cancer within the last 5 years. Patients with treated basal cell carcinoma were eligible.
- •Patients with a history of life-threatening pulmonary obstruction, or a history of cystic fibrosis or bronchiectasis.
- •Patients who had undergone thoracotomy with pulmonary resection. Patients with a history of thoracotomy for other reasons were evaluated as per the first exclusion criterion (i.e., significant disease other than COPD).
- •Patients with an upper respiratory tract infection in the 6 weeks prior to the Screening Visit (Visit 1) or during the run-in period.
- •Further exclusion criteria apply.
结局指标
主要结局
Endurance time during a constant work rate exercise test to symptom limitation
时间窗: 2 hours and 15 minutes after trial medication administration on Day 42
次要结局
- Physician's Global Assessment(6 weeks)
- Evaluation of slow vital capacity (SVC)(6 weeks)
- Constant work rate exercise test to symptom limitation(8 hours post-dose after 6 weeks of treatment)
- Occurrence of Adverse Events(6 weeks)
- Breathing discomfort during constant work rate exercise test as measured by the modified Borg Scale(6 weeks)
- Dynamic lung hyperinflation during exercise as determined by IRVdyn (IC minus VT) and EELVdyn (TLC)(6 weeks)
- Evaluation of VE and VEcap during exercise (selected centers)(6 weeks)
- Evaluation of static lung hyperinflation as measured by RV/TLC and by TGV(FRC)/TLC(6 weeks)
- Evaluation of TAC (TAV = TLC(BOX)-VA(IG))(6 weeks)
- Evaluation of maximal expiratory flow rates and volumes FEV1, FVC, FEF25-75%, FEF50%, FEF75%, SVC(6 weeks)
- Evaluation of TGV, Raw, SGaw and RV(6 weeks)
- Changes in Physical examination and ECG(6 weeks)
- Evaluation of SaO2, VO2, VCO2, Ti, Te, VE, VT, breathing frequency (f) during constant work rate exercise test(6 weeks)
- Assessement of Pulse/heart rate and blood pressure in conjunction with spirometry and exercise(6 weeks)
研究者
研究点 (28)
Loading locations...
相似试验
已完成
3 期
Effect of Tiotropium on Exercise Tolerance in Patients With Chronic Obstructive Pulmonary Disease (COPD)Pulmonary Disease, Chronic ObstructiveNCT02172300Boehringer Ingelheim198
已完成
不适用
Tiotropium Induced Bronchodilation in Lung CT Scored EmphysemaCOPDEmphysemaNCT00570544Gelb, Arthur F., M.D.29
已完成
不适用
Effects of Aerobe Interval Training and Moderate Continuous Training in Chronic Obstructive Pulmonary Disease PatientsCOPDChronic Obstructive Pulmonary DiseaseNCT00908765Norwegian University of Science and Technology20
已完成
4 期
Differential Trough Effects of 'Triple Therapy' on Pulmonary Function in Chronic Obstructive Pulmonary Disease (COPD)COPDNCT00996697Brian J Lipworth23
已完成
3 期
Effect of Tiotropium on Airway Diameter in Patients With Chronic Obstructive Pulmonary Disease (COPD)Pulmonary Disease, Chronic ObstructiveNCT02172391Boehringer Ingelheim81